Reuters: Regulatory News: U.S. FDA denies approval to expanded use of J&J/Bayer's Xarelto

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

U.S. FDA denies approval to expanded use of J&J/Bayer's Xarelto Mar 5th 2013, 00:37 March 4 | Mon Mar 4, 2013 7:37pm EST March 4 (Reuters) - Johnson & Johnson said U.S. health regulators denied approval to an expanded use of its blood thinner, Xarelto, to reduce the risk of heart attacks and strokes in patients with acute coronary syndrome. The drug, which J&J has developed in partnership with German drugmaker Bayer AG, was earlier denied approval in June for the same use, as a panel to the U.S. Food and Drug Administration raised concerns about missing trial data and bleeding risks. In response to this, J&J submitted to the FDA additional data that showed the benefits and risks of Xarelto in patients who had withdrawn from the study. "While we saw an increase in major bleeding, there was no increase in fatal bleeding," said Dr. Christopher Nessel, Vice President at Janssen, a unit of J&J. Xarelto is already approved for six other uses, including reducing the risk of blood clots in patients who have had hip and knee replacement surgery, and to prevent strokes among people with a type of irregular heartbeat called atrial fibrillation. J&J said on Monday it was evaluating the rejection letter issued by the FDA.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions